



Oregon Prescription Drug Affordability Board (PDAB) Regular Meeting
Wednesday, November 15, 2023
Minutes
Approved by the board on Dec. 13, 2023

Web link to the meeting video: <https://www.youtube.com/watch?v=6Gk2182MFZw>

Web link to the meeting materials: <https://dfr.oregon.gov/pdab/Documents/20231115-PDAB-document-package.pdf>.

Web link to Excel spreadsheets and data information: <https://dfr.oregon.gov/pdab/Pages/data.aspx>

Call to order and roll call: Chair Akil Patterson called the meeting to order at 9:30 am and roll was called.

Board members present: Chair Akil Patterson, Vice Chair Shelley Bailey, Dr. Richard Bruno, Dr. Amy Burns, Dr. Daniel Hartung.

Board members absent: Robert Judge, John Murray

Approval of minutes: Richard Bruno made a motion and Shelley Bailey provided a second to approve the minutes on [Pages 3-4](#) in the agenda packet. [View the approval in the meeting video at 00:01:01.](#)

MOTION to approve the minutes.

Board Vote:

Yes: Richard Bruno, Amy Burns, Daniel Hartung, Vice Chair Shelley Bailey, Chair Akil Patterson

No: None

Motion passed 5-0

Program update by Executive Director Ralph Magrish. [View the executive director's report in the meeting video at minute 00:02:15.](#)

Presentation on insulin by Dr. Yan Emily Yuan of Brigham and Women's Hospital in Boston, Mass: View the slide presentation on [Pages 7-29](#) of the agenda packet. [View Dr. Yuan's presentation in the meeting video at minute 00:07:18.](#)

OAR 925-200-0010 board discussion and vote on insulin subset list: Amanda Claycomb, data analyst, began the discussion about the data on [Pages 30-39](#) of the agenda packet. The [Excel files](#) are located on the PDAB website under the heading "Data for board review on November 15, 2023." [View video of the board discussion and votes on subset of insulin products at 00:30:38.](#) The board voted on subset lists for long acting, short acting and rapid-acting insulin. See [Table 1](#) for the list of drugs the board voted on and approved. While the board voted on four motions, one motion failed but passed after an amendment to include an additional insulin product. The votes were:

Dr. Bruno made the motion and Shelley Bailey provided the second for the long-acting insulin list.

MOTION on the long-acting subset list of Tresiba, Soliqua, Zultophy.

Board Vote:

Yes: Daniel Hartung

No: Amy Burns, Richard Bruno, Shelley Bailey, Akil Patterson

Motion failed 1-4.

Amy Burns made the amended motion to also include the flex pen and Richard Bruno provided the second.

MOTION on the long-acting subset list of Tresiba, Tresiba FlexTouch, Soliqua, Zultophy.

Board Vote:



Yes: Daniel Hartung, Amy Burns, Richard Bruno, Shelley Bailey, Akil Patterson

No: None

Motion passed 5-0.

Shelley Bailey made the motion and Richard Bruno provided the second for the short-acting insulin list.

MOTION on the short-acting subset list of HumuLIN R and HumuLIN R U-500 KwikPen.

Board Vote:

Yes: Daniel Hartung, Amy Burns, Richard Bruno, Shelley Bailey, Akil Patterson

No: None

Motion passed 5-0.

Richard Bruno made the motion and Amy Burns provided the second for the rapid-acting insulin list.

MOTION on the rapid-acting subset list of Insulin Aspart, Insulin Aspart PenFill, Lyumjev, Lyumjev KwikPen.

Board Vote:

Yes: Daniel Hartung, Amy Burns, Richard Bruno, Shelley Bailey, Akil Patterson

No: None

Motion passed 5-0.

Table 1: Board approved subset list of insulin products pursuant to OAR 925-200-0010

Insulin type	Proprietary name(s)	Non-proprietary name
Long-Acting	Tresiba	Insulin Degludec
Long-Acting	Tresiba FlexTouch	Insulin Degludec
Long-Acting	Soliqua	Insulin Glargine-Lixisenatide
Long-Acting	Xultophy	Insulin Degludec-Liraglutide
Rapid-Acting	Insulin Aspart	Insulin Aspart
Rapid-Acting	Insulin Aspart PenFill	Insulin Aspart
Rapid-Acting	Lyumjev	Insulin Lispro-aabc
Rapid-Acting	Lyumjev KwikPen	Insulin Lispro-aabc
Short-Acting	HumuLIN R	Insulin Regular (Human)
Short-Acting	HumuLIN R U-500 KwikPen	Insulin Regular (Human)

OAR 925-200-0010 board discussion and vote on orphan designation of prescription drugs and vote on updated subset list: Amanda Claycomb, data analyst, reviewed data changes on [Pages 49-52](#) of the agenda packet. [View the board discussion in the meeting video at 01:34:45](#). Board members voted on an update subset list of prescription drugs as shown in [Table 2](#).

Shelley Bailey made the motion and Richard Bruno provided the second for updated subset list.

MOTION on updated subset list of prescription drugs as shown in Table 2:

Board Vote:

Yes: Daniel Hartung, Amy Burns, Richard Bruno, Shelley Bailey

No: None

Abstain: Akil Patterson

Motion passed 4-0.



Table 2: Board approved updated subset list of prescription drugs pursuant to OAR 925-200-0010

Proprietary name(s)	Non-proprietary name
Albuterol Sulfate / Albuterol Sulfate ER / Albuterol Sulfate HFA / ProAir HFA / ProAir RespiClick / Proventil HFA / Ventolin HFA	Albuterol Sulfate
Budesonide-Formoterol Fumarate / Symbicort	Budesonide-Formoterol Fumarate Dihydrate
Bunavail / Buprenorphine HCl-Naloxone HCl / Suboxone / Zubsolv	Buprenorphine HCl-Naloxone HCl Dihydrate
Cosentyx / Cosentyx Sensoready Pen / Cosentyx Sensoready	Secukinumab
Creon / Pancreaze / Pertzye / Viokace / Zenpep	Pancrelipase (Lipase-Protease-Amylase)
Entyvio	Vedolizumab
Genvoya	Elvitegravir-Cobicistat-Emtricitabine-Tenofovir Alafenamide
Inflectra	Infliximab-dyyb
Ocrevus	Ocrelizumab
Rybelsus / Ozempic	Semaglutide
Shingrix	Zoster Vaccine Recombinant Adjuvanted
Skyrizi / Skyrizi Pen	Risankizumab-rzaa
Tremfya	Guselkumab
Triumeq / Triumeq PD	Abacavir-Dolutegravir-Lamivudine
Trulicity	Dulaglutide
Vyvanse	Lisdexamfetamine Dimesylate

Board review of policy submissions: Ralph Magrish, executive director, and Cortnee Whitlock, policy analyst, reviewed the proposed policy recommendations submitted by the public shown on [Pages 61-66](#) in the agenda packet. [View the discussion in the meeting video at 01:46:36](#). The board voted to approve policy recommendations 1, 2, and 5, with 4 having provisional approval based on the board learning more information at the Dec. 13 meeting. The board will review and vote on the final report with recommendations on Dec. 13.

Amy Burns made the motion and Daniel Hartung provided the second.

MOTION to approve policy recommendations 1, 2, and 5, with 4 having provisional approval.

Board Vote:

Yes: Daniel Hartung, Amy Burns, Richard Bruno, Shelley Bailey, Akil Patterson

No: None

Motion passed 5-0.

Announcements: Ralph Magrish said staff will present a work plan and affordability review template for the board to review at the Dec. 13 meeting. The board will announce in December how and when manufacturers may submit information about prescription drugs. All public comments are posted on the PDAB website. In addition, Dr. Richard Bruno announced his resignation from the board beginning in January due to taking a new position as the Multnomah County Health Officer. [View these comments in the meeting video at 2:14:42.](#)



Public comment: Chair Akil Patterson called on the people who signed up to speak to the board: John Mullin, president, Oregon Coalition for Affordable Prescriptions (OCAP); Dharia McGrew, director of state policy, PhRMA; Brian Warren, senior director, state government affairs; Biotechnology Innovation Organization; and Terri Lee, vice president of state government affairs and policy, Merck. [View the oral testimony in the meeting video at 02:19:57.](#)

In addition, OCAP, Bio and Oregon Bioscience Association, Bristol Myers Squibb, Genentech, Merck, and PhRMA provided written testimony to the board. [The written testimony is posted on the PDAB website.](#)

Adjournment: The meeting was adjourned at 12 p.m. by Chair Patterson.